There are many factors that impact the successful transition of a medicine from the unlicensed to commercial marketplace and a thorough, robust strategy is vital to realise a medicine’s full potential. For over 30 years, Clinigen has been helping patients gain access to unlicensed medicines across the globe, giving us a unique insight into this environment.
Our Asset Strategy service combines our extensive experience with individual expertise in core marketing disciplines, to provide a comprehensive roadmap for an asset across:
- Patient Forecasting > Projected patient numbers for early access programs to assist in client forecasting and modelling
- Regulatory Landscape > Review of regulatory environment across markets to identify optimal approach to medicine access
- Operational Footprint > Identification of roadblocks and solutions to enable comprehensive access to client’s Investigational Medicines across global markets
- Communication Planning > Identification of key opportunities for complaint communications for all relevant stakeholders
Our Consulting Services provide tailored solutions for pharmaceutical and biotech companies.